Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Accuretic · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Accuretic™ Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Accuretic™ Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Accuretic is a combination tablet containing quinapril hydrochloride and hydrochlorothiazide, used in healthy volunteers in clinical studies. It is being developed by Viatris Inc. (VTRS) as a small molecule product. The drug is currently in Phase 1 clinical development, with studies focused on healthy participants.
Accuretic is developed by Viatris Inc., a global healthcare company traded on the NASDAQ under the ticker VTRS. The company is conducting clinical trials to evaluate the product in healthy volunteers. As of the latest data, Accuretic is in Phase 1 development.
Accuretic is in Phase 1 clinical development. It has completed two Phase 1 trials, both involving healthy volunteers. The drug is investigational and not yet approved for marketing. Viatris Inc. (VTRS) is the developer of this small molecule product.
Accuretic has completed two Phase 1 clinical trials. NCT00648011 is a food study comparing quinapril HCl and hydrochlorothiazide tablets 20 mg/25 mg to Accuretic tablets 20 mg/25 mg, enrolling 44 participants. NCT00649441 is a fasting study with the same comparison, enrolling 60 participants. Both were conducted in the United States.
Accuretic is a combination tablet containing quinapril hydrochloride and hydrochlorothiazide. Clinical trials have compared the fixed-dose combination to separate tablets of the two active ingredients. The studies were designed to assess bioequivalence under fed and fasting conditions in healthy volunteers.